Tabrecta (capmatinib) has potential interactions with other medications and some supplements. These interactions could affect how well the drug works or cause harmful effects. Tabrecta is used in ...

What is the current share price of Incyte Corp (INCY)? Incyte Corp's (INCY) current share price is $64.25. This constitutes a price movement of 1.48% when compared to the share price 7 days ago and is ...

In the US, it is competing in the METex14-positive NSCLC market with Novartis/Incyte's rival MET inhibitor Tabrecta (capmatinib). The EAMS opinion is based on results from the phase 2 VISION study ...

It is the first cMET inhibitor to reach the market in China, ahead of rival therapies such as Novartis/Incyte's Tabrecta (capmatinib) and Merck KGaA's Tepmetko (tepotinib), which have both been ...